Avandia (rosiglitazone): REMS – Risk of Cardiovascular Events

Audience: Endocrinology, Cardiology [Posted 09/23/2010]

ISSUE: FDA notified healthcare professionals and patients that it will significantly restrict the use of the diabetes drug Avandia (rosiglitazone) to patients with Type 2 diabetes who cannot…



No related posts.